MGMT and neoplasm: Moreover, preliminary data from a phase 3 randomized, double-blinded, placebo-controlled clinical trial of an autologous tumor lysate-pulsed dendritic cell vaccine (DCVax®-L) for newly diagnosed GBM showed that the median OS was 34.7 months (95% CI 27.0–40.7) and 19.8 months (95% CI 17.9–21.7), in patients with methylated and unmethylated MGMT, respectively [60].